Biotech

#Biotech #Investment #Switzerland

Swiss biotech saw record revenues in 2025, report says 

The Swiss biotech industry recorded its highest ever revenues in 2025, a new report shows.  The 2026 Swiss Biotech Report says the industry saw record revenues of CHF 7.5 billion (€8.2 billion) in 2025, up from CHF 7.2 billion (€7.9 billion) in 2024.  Employment in… Read More

#News

#AstraZeneca #BioIndustry Association #Biotech #Boehringer Ingelheim #FDA #Gene therapy #Genetics #Hearing Loss #HIV #Investment #Malaria #Novartis #UK #WHO

DDW Highlights: 6 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, the UK made headlines for both the investment it has attracted and… Read More

#Podcasts

#AstraZeneca #BioIndustry Association #Biotech #Boehringer Ingelheim #FDA #Gene therapy #Genetics #Hearing Loss #HIV #Investment #Malaria #Novartis #UK #WHO

This week in Drug Discovery (27 April – 1 May) 

News round-up for 27 April – 1 May by Bruno Quinney, Content Team at DDW.  This week, the UK has made headlines for both the investment it has attracted and the clinical trial reforms it has rolled out. Elsewhere, the world’s first antimalarial drug for newborns could soon address a critical unmet… Read More

#News

Cell and gene therapies
#ASGCT #Biotech #Cell and gene therapy

Coave to unveil capsid technology at ASGCT 2026 

Biotechnology company Coave Therapeutics is set to unveil its OneAAV universal capsid at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting.  The company will deliver two oral presentations and present two posters at the event, being held 11 – 15 May in Boston, US, showing data… Read More

#News

Cancer immunotherapy
#Asgard Therapeutics #Biotech #Cancer immunotherapy #Tumour biology

Gene-based immunotherapy could reprogramme tumour cells 

Biotechnology company Asgard Therapeutics is set to announce preclinical results showing its gene-based cancer immunotherapy could reprogramme tumour cells.  The company will present data on AT-108, a first-in-class, off-the-shelf cancer immunotherapy, in an oral presentation at the ASGCT Annual Meeting, held from 11-15 May in Boston,… Read More

#News

Swiss Biotech Day 2026
#Biotech #Events #Switzerland

Hear from Switzerland’s pharma leaders at Swiss Biotech Day 2026

Swiss Biotech Day, first launched in 2021, will be held this year at Congress Center Basel on 4-5 May.  The day provides a chance to explore advances in R&D, manufacturing, data management, AI and innovative financing.  The 2026 Plenary Sessions will include a fireside session… Read More

#News

Proteomics
#Biotech #Oncology #Precision medicine #Proteomics

Nomic and Broad Clinical Labs to build proteomics platform 

Biotechnology company Nomic Bio has announced a partnership with Broad Clinical Labs (BCL) to build a scalable proteomics platform.  The organisations will look to integrate Nomic’s Omni 1000 solution into BCL’s existing capabilities to develop new application-specific solutions.   Based on nELISA technology, Nomic says Omni 1000 measures… Read More

#News

ulcerative colitis
#Biotech #Clinical trial #Ulcerative colitis (UC)

Spyre Therapeutics reports positive data for UC treatment 

Biotechnology company Spyre Therapeutics has reported positive results for its treatment for moderate-to-severely-active ulcerative colitis (UC).  SPY001, a potential best-in-class anti-α4β7, met its primary endpoint in a Phase II trial, with a significant reduction of 9.2 points from baseline at Week 12 in Robart’s Histopathology Index (RHI) score. Read More

#News

#Asgard Therapeutics #Biotech

Asgard Therapeutics appoints Dr Wolfram Brugger as CMO 

Biotechnology company Asgard Therapeutics has appointed Dr Wolfram Brugger as Chief Medical Officer.  Brugger, who has been involved in more than 130 Phase I to III clinical oncology trials across a wide variety of cancer types, has been appointed to strengthen Asgard’s leadership as it prepares to transition… Read More

#News

Swiss Biotech Day 2026
#Biotech #Drug discovery #Events #Switzerland

Register now for Swiss Biotech Day 2026

Swiss Biotech Day, first launched in 2021, will be held this year at Congress Center Basel on 4-5 May.  The event has seen remarkable growth every year and has become a key global biotechnology conference for life sciences professionals, fostering international collaboration and impactful partnerships.  … Read More

#News

#Biotech #Broken String Biosciences

Broken String rebrands to support genome programmes 

Biotechnology company Broken String Biosciences has rebranded as the company repositions its strategic focus.  The company will now support early discovery programmes through to investigational new drug (IND)-enabling studies, moving away from its focus on being a specialist technology provider.  Broken String Biosciences, a company… Read More

#News

Antibodies
#Antibodies #Biotech #Drug discovery #In Focus Report

The opportunities & challenges for antibody-based therapies

Download this In Focus report to learn about the market for antibody-based therapies and the scientific developments behind recent advances in these drugs. Read about: Where investment lies in the antibody-based drugs market Why mAbs are at the heart of phasing out animal testing The data bottleneck in AI antibody… Read More

#News

Cancer research
#Alpha-1 antitrypsin deficiency #Beam Therapeutics #Biotech

Beam reports positive data for genetic disease treatment 

Biotechnology company Beam Therapeutics has reported encouraging data for its treatment for the genetic disease Alpha-1 Antitrypsin Deficiency (AATD).  Beam announced BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation designed to directly correct the underlying genetic mutation that causes AATD, has shown a well-tolerated safety profile and efficacy in a… Read More

#News

CAR-T in multiple myeloma
#Biotech #Cancer research #CAR-T #Drug discovery #Oncology

The next generation of CAR-T cell therapies

Drug Discovery World Editor Reece Armstrong speaks to Dr Jan Davidson-Moncada, Chief Medical Officer at Imviva Biotech about the development of CAR-T cell therapies and the company’s activities in this space.   RA: What are the biggest challenges when developing CAR-T cell therapies?   JDM: CAR-T therapies face several formidable barriers. Autologous approaches made from a patient’s own T-cells are… Read More

#Exclusive Content

#Biotech #Drug discovery #Financing #Oncology

Laigo Bio raises $17m to advance oncology pipeline  

Biotech company Laigo Bio has completed the second close of its seed financing round with an additional $5.5 million bringing the total investment to $17 million.   Laigo will use the seed financing to accelerate the development of its Surface Removal Targeting Chimeras (SureTACs) oncology programmes towards the clinic. It will also advance three… Read More

#Business & Investment #News

Heart in a box
#Biotech #Cardio #IsomAb

IsomAb appoints CEO to lead development of angina treatment 

Biotechnology company IsomAb has appointed Dr Philip Brainin as Chief Executive Officer as it looks to enter clinic with a treatment for chronic stable angina (CSA).  Brainin arrives with experience in cardiovascular medicine, clinical research, and venture investing across EU and US biotechnology companies. He has previously invested in… Read More

#News